CD19 and acute myeloid leukemia: In addition to T-ALL, CD19-CAR-modified NK cell-based immunotherapy can be used to treat primary chronic lymphocytic leukemia (CLL) (Boissel et al., 2013), acute myeloid leukemia (AML, ClinicalTrials.gov.NCT00995137), myelodysplastic syndromes (Gleason et al., 2014), and B cell leukemia and lymphoma (Oelsner et al., 2017).